Study to Evaluate the Pharmacokinetics, Safety and Tolerability of Intravenous Secukinumab in Patients With GCA or PMR

NCT06130540 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

65

Enrollment

INDUSTRY

Sponsor class

Conditions

Giant Cell Arteritis
Polymyalgia Rheumatica

Interventions

DRUG: Secukinumab

Sponsor

Novartis Pharmaceuticals